<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is the leading cause of <z:hpo ids='HP_0003774'>end stage renal disease</z:hpo> in the Western world </plain></SENT>
<SENT sid="1" pm="."><plain>30-35% of the patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> will have micro- or macroalbuminuria, warranting yearly screening </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment to prevent diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is multifactorial, adressing known progression promoters such as blood pressure, glycaemia, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and smoking and includes antithrombotic prophylaxis </plain></SENT>
<SENT sid="3" pm="."><plain>Although progress has been made over the last few decades, there is still an unmet need for improved screening, prevention and treatment since both cardiac and renal morbidity and mortality remains severe in this group of patients </plain></SENT>
</text></document>